Improving Lentiviral Vector Yield with 2G UNic™ Technology
Lentiviral vectors (LVs) are indispensable for ex vivo gene therapies, but producing them at scale while maintaining high quality and yield remains a major challenge. In this expert-led webinar, you’ll learn how NecstGen and ProteoNic are tackling this issue together.
If you missed the live session, you can now watch the full webinar on demand.
What you’ll learn:
-
A practical overview of the lentiviral production process, from seed train to downstream processing.
-
Common bottlenecks that cap LV titers—despite optimal transfection conditions.
-
How ProteoNic’s 2G UNic™ technology enhances translational efficiency in host cells to improve LV yield.
-
Real-world results and insights from Maurice van der Heijden (ProteoNic) and Diederik Lokhorst (NecstGen).
Whether you’re troubleshooting your own production process or exploring next-gen tools to boost yields and reduce costs, this replay offers valuable technical insights into overcoming a key barrier in gene therapy manufacturing.
If you have additional questions, we invite you to share your questions.
